STTK - Why Is Blood Cancer-Focused Shattuck Labs Stock Soaring Today? | Benzinga
Shattuck Labs Inc (NASDAQ: STTK) announced initial topline dose-expansion data from its ongoing Phase 1A/B trial of SL-172154 in combination with Azacitidine (AZA) in frontline high-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant (TP53m) acute myeloid leukemia (AML) patients.
The study observed an Objective Response Rate (ORR) of 79% in frontline HR-MDS patients, primarily with TP53 mutations, with an initial complete response (CR)/marrow complete response (mCR) rate of 64%.
Observed 27% initial CR/complete response with incomplete hematologic recovery (CRi) in frontline TP53m AML patients, and 5/11 evaluable ...